Modified BoNT/A-B Receptor Fusion for Longer Cervical Dystonia Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cervical dystonia, such as BoNT/A, have limitations including short duration of action, frequent injections, complications, and challenges in balancing dosage to avoid toxicity, leading to suboptimal therapy and increased health and logistical burdens.
Innovation Solution
A modified BoNT/A with a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain, which enhances retention and duration of action, allowing for higher doses and tailored administration to affected neck muscles, reducing frequency of injections and improving safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional BoNT/A products are used for treating cervical dystonia, then the treatment effect is achieved, but the duration of action is short (12-14 weeks) requiring frequent injections
Solution Approach 1:
The patent applies parameter changes by modifying the molecular structure of BoNT/A through fusion with the Hc domain from BoNT/B. This structural parameter change results in altered pharmacokinetic properties, specifically extending the duration of action from 12-14 weeks to potentially longer periods, thereby reducing the frequency of injections required
Solution Approach 2:
The invention creates a composite toxin molecule by fusing the catalytic domain of BoNT/A with the Hc domain of BoNT/B. This composite structure combines functional elements from both neurotoxins, where the BoNT/A light chain provides the paralytic effect and the BoNT/B Hc domain contributes to extended retention at the injection site, achieving both efficacy and prolonged duration
2Duration of action of moving object
If higher doses of BoNT/A are administered to extend duration of action, then treatment effectiveness may improve, but patient toxicity increases
Solution Approach 1:
The patent modifies the dosing parameter by establishing a new dosage range (300-1000 units per injection site, 1500-5000 units total per session) for the modified BoNT/A-Hc. This parameter change is based on the altered pharmacokinetic profile of the modified toxin, which achieves extended duration at lower doses compared to conventional BoNT/A, thereby improving the therapeutic index and reducing toxicity risks
3Reliability
If conventional BoNT/A treatment regimens are used, then treatment can be administered, but dosage balancing is complicated leading to under-dosing to avoid toxicity
Solution Approach 1:
The patent establishes new dosing parameters specifically for the modified BoNT/A-Hc, including unit definitions (1 unit = 0.025-0.05 µg), injection site dosage ranges (300-1000 units), and total session dosage limits (1500-5000 units). These standardized parameters simplify clinical decision-making and reduce the risk of under-dosing while maintaining safety margins
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified BoNT/A provides a longer-lasting treatment with improved safety, enabling more effective and less frequent administration, better tailored to individual patient needs, reducing complications and improving quality of life.
Implementation Method 1
BoNT/A selectively inhibits the release of acetylcholine from the presynaptic nerve terminals and thus blocks cholinergic transmission at the neuromuscular junction inducing a reduction in the muscle contraction and muscle tone
Data Source
Figure 1~2
Figure 3A~3B
Figure 3C~3D
AI summary
The present invention is directed to treatment of cervical dystonia using a modified BoNT/A, including a modified botulinum neurotoxin A (BoNT/A) for use in treating cervical dystonia, wherein the modified BoNT/A is administered by intramuscular injection to an affected neck muscle of a subject, wherein the modified BoNT/A is administered by way of a unit dose of 750 pg to 17,000 pg of modified BoNT/A, wherein at least a single unit dose is administered to the affected neck muscle, wherein the total dose administered during the treatment is up to 170,000 pg of modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light- chain and translocation domain, and a BoNT/B receptor binding domain (HC domain). Also provided are associated methods, uses, unit dosage forms, and kits.